Difference between revisions of "Cytogenetic tests"

From Libre Pathology
Jump to navigation Jump to search
m (→‎ISH: w)
 
(5 intermediate revisions by the same user not shown)
Line 4: Line 4:


Findings:
Findings:
*5q deletion seen in myelodysplastic syndromes.<ref>{{Cite journal  | last1 = Nimer | first1 = SD. | title = Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. | journal = J Clin Oncol | volume = 24 | issue = 16 | pages = 2576-82 | month = Jun | year = 2006 | doi = 10.1200/JCO.2005.03.6715 | PMID = 16735711 }}
*5q deletion seen in [[myelodysplastic syndromes]].<ref>{{Cite journal  | last1 = Nimer | first1 = SD. | title = Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. | journal = J Clin Oncol | volume = 24 | issue = 16 | pages = 2576-82 | month = Jun | year = 2006 | doi = 10.1200/JCO.2005.03.6715 | PMID = 16735711 }}
</ref>
</ref>
*Y deletion in [[MDS]]<ref name=pmid21269692>{{Cite journal  | last1 = Mallo | first1 = M. | last2 = Luño | first2 = E. | last3 = Sanzo | first3 = C. | last4 = Cervera | first4 = J. | last5 = Haase | first5 = D. | last6 = Schanz | first6 = J. | last7 = García-Manero | first7 = G. | last8 = Del Cañizo | first8 = C. | last9 = Sanz | first9 = GF. | title = Clinical impact of the clone size in MDS cases with monosomy 7 or 7q deletion, trisomy 8, 20q deletion and loss of Y chromosome. | journal = Leuk Res | volume =  | issue =  | pages =  | month = Jan | year = 2011 | doi = 10.1016/j.leukres.2011.01.003 | PMID = 21269692 }}
*Y deletion in [[MDS]]<ref name=pmid21269692>{{Cite journal  | last1 = Mallo | first1 = M. | last2 = Luño | first2 = E. | last3 = Sanzo | first3 = C. | last4 = Cervera | first4 = J. | last5 = Haase | first5 = D. | last6 = Schanz | first6 = J. | last7 = García-Manero | first7 = G. | last8 = Del Cañizo | first8 = C. | last9 = Sanz | first9 = GF. | title = Clinical impact of the clone size in MDS cases with monosomy 7 or 7q deletion, trisomy 8, 20q deletion and loss of Y chromosome. | journal = Leuk Res | volume =  | issue =  | pages =  | month = Jan | year = 2011 | doi = 10.1016/j.leukres.2011.01.003 | PMID = 21269692 }}
Line 17: Line 17:
|-
|-
| BCR/ABL1
| BCR/ABL1
| CML or ALL
| [[CML]] or ALL
| Tx (imatinib)
| Tx: [[imatinib]]
|-
|-
| MLL
| MLL<ref>{{OMIM|159555}}</ref>
| ALL or AML
| ALL or AML
| rearrangment --> marker of poor prognosis<ref>{{Cite journal  | last1 = Liedtke | first1 = M. | last2 = Cleary | first2 = ML. | title = Therapeutic targeting of MLL. | journal = Blood | volume = 113 | issue = 24 | pages = 6061-8 | month = Jun | year = 2009 | doi = 10.1182/blood-2008-12-197061 | PMID = 19289854 }}
| rearrangment --> marker of poor prognosis<ref>{{Cite journal  | last1 = Liedtke | first1 = M. | last2 = Cleary | first2 = ML. | title = Therapeutic targeting of MLL. | journal = Blood | volume = 113 | issue = 24 | pages = 6061-8 | month = Jun | year = 2009 | doi = 10.1182/blood-2008-12-197061 | PMID = 19289854 }}
Line 43: Line 43:
| BCL2
| BCL2
| [[follicular lymphoma]]
| [[follicular lymphoma]]
|
| t(14;18)(q32;q21)<ref name=pmid21192062>{{Cite journal  | last1 = Yanai | first1 = S. | last2 = Nakamura | first2 = S. | last3 = Takeshita | first3 = M. | last4 = Fujita | first4 = K. | last5 = Hirahashi | first5 = M. | last6 = Kawasaki | first6 = K. | last7 = Kurahara | first7 = K. | last8 = Sakai | first8 = Y. | last9 = Matsumoto | first9 = T. | title = Translocation t(14;18)/IGH-BCL2 in gastrointestinal follicular lymphoma: correlation with clinicopathologic features in 48 patients. | journal = Cancer | volume =  | issue =  | pages =  | month = Dec | year = 2010 | doi = 10.1002/cncr.25811 | PMID = 21192062 }}</ref>
 
|-
|-
| ERBB2 (HER2)
| ERBB2 (HER2)
| [[breast cancer]]
| [[breast cancer]]
| prognostic, Tx (trastuzumab)
| prognostic, Tx ([[trastuzumab]])
|-
|-
| EWSR1
| EWSR1

Latest revision as of 17:09, 14 January 2012

Thsi article is a list of common cytogenetic tests. An introduction to cytogenetics is in the cytogenetics article.

Karyotyping

Findings:

ISH

Cytogenetic tests at one hospital:[3]

Test Parameters Notes
BCR/ABL1 CML or ALL Tx: imatinib
MLL[4] ALL or AML rearrangment --> marker of poor prognosis[5]
MYC Burkitt's lymphoma + others prognostic
ALK DLBCL - BCL6, BCL2 or MYC ?
MALT1 MALT lymphoma trisomy 3, trisomy 18
CCND1 mantle cell lymphoma ?
BCL2 follicular lymphoma t(14;18)(q32;q21)[6]
ERBB2 (HER2) breast cancer prognostic, Tx (trastuzumab)
EWSR1 small round blue cell tumour (suspected Ewing sarcoma)

See also

References

  1. Nimer, SD. (Jun 2006). "Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.". J Clin Oncol 24 (16): 2576-82. doi:10.1200/JCO.2005.03.6715. PMID 16735711.
  2. Mallo, M.; Luño, E.; Sanzo, C.; Cervera, J.; Haase, D.; Schanz, J.; García-Manero, G.; Del Cañizo, C. et al. (Jan 2011). "Clinical impact of the clone size in MDS cases with monosomy 7 or 7q deletion, trisomy 8, 20q deletion and loss of Y chromosome.". Leuk Res. doi:10.1016/j.leukres.2011.01.003. PMID 21269692.
  3. Kamel-Reid, Suzanne. University Health Network / Department of Pathology. Cancer Cytogenetics & Molecular Diagnostics Laboratories. Test Requisition. August 2010.
  4. Online 'Mendelian Inheritance in Man' (OMIM) 159555
  5. Liedtke, M.; Cleary, ML. (Jun 2009). "Therapeutic targeting of MLL.". Blood 113 (24): 6061-8. doi:10.1182/blood-2008-12-197061. PMID 19289854.
  6. Yanai, S.; Nakamura, S.; Takeshita, M.; Fujita, K.; Hirahashi, M.; Kawasaki, K.; Kurahara, K.; Sakai, Y. et al. (Dec 2010). "Translocation t(14;18)/IGH-BCL2 in gastrointestinal follicular lymphoma: correlation with clinicopathologic features in 48 patients.". Cancer. doi:10.1002/cncr.25811. PMID 21192062.